A Phase 3 interventional study of Evolocumab and Placebo in Hypercholesterolemia, sponsored by Amgen. Completed at 96 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-07-22.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.
Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 8th largest by enrollment, is one of 4 that started in 2012, is one of 22 in phase 3, and was the 5th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 24 · Phase 4 7
First in 2011; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 905 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 308 across the 36 interventional studies. Of the 32 that completed or were terminated, 31 (97%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
35 studies in Hypercholesterolemia by Amgen: 1 open now, 1 under way, none of them phase 3. Of 34 finished, 30 (88%) have results posted.
Among the 35 studies in Hypercholesterolemia by Amgen, this one is the 8th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2012, is one of 22 in phase 3, and was the 5th registered.
Amgen’s Hypercholesterolemia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing evolocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 35 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC) evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering therapy.
Eligible participants with screening central laboratory low-density lipoprotein cholesterol (LDL-C) values ≥ 75 mg/dL (1.9 mmol/L) were instructed to follow National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP) Therapeutic Lifestyle Changes (TLC) diet and were assigned to 1 of the following 4 background lipid-lowering therapies for a 4-week stabilization period based upon their screening LDL-C and its distance from the individual's required goal as stipulated by their NCEP ATP III risk category:
If the participant met entry criteria at the end of the lipid stabilization period they were randomized 2:1 to receive evolocumab 420 mg or placebo subcutaneously once a month for 52 weeks in addition to their background therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Fasting LDL-C ≥ 75 mg/dL and meeting the following LDL-C values on background lipid-lowering therapy:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received evolocumab 420 mg subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
Biological: Evolocumab · Drug: Atorvastatin · Drug: Ezetimibe · Other: Diet Only
Participants received placebo subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
Biological: Placebo · Drug: Atorvastatin · Drug: Ezetimibe · Other: Diet Only
Administered by subcutaneous injection once a month
Also known as: AMG 145, Repatha
Administered by subcutaneous injection once a month
Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.
Background lipid lowering therapy: ezetimibe 10 mg orally once a day
Diet only, no lipid lowering background drug given
Percent Change From Baseline in LDL-C at Week 52
Cholesterol was measured by means of ultracentrifugation.
Time frame: Baseline and Week 52
Change From Baseline in LDL-C at Week 52
Cholesterol was measured by means of ultracentrifugation.
Time frame: Baseline and Week 52
Percentage of Participants With an LDL-C Response at Week 52
An LDL-C response is defined as LDL-C level \< 70 mg/dL (1.8 mmol/L) at Week 52.
Time frame: Week 52
Percent Change From Baseline in LDL-C at Week 12
Cholesterol was measured by means of ultracentrifugation.
Time frame: Baseline and Week 12
Percent Change From Baseline in Total Cholesterol at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Total Cholesterol at Week 52
Time frame: Baseline and Week 52
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 52
Time frame: Baseline and Week 52
Percent Change From Baseline in Apolipoprotein B at Week 52
Time frame: Baseline and Week 52
Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 52
Time frame: Baseline and Week 52
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 52
Time frame: Baseline and Week 52
Percent Change From Baseline in Lipoprotein(a) at Week 52
Time frame: Baseline and Week 52
Percent Change From Baseline in Triglycerides at Week 52
Time frame: Baseline and Week 52
Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 52
Time frame: Baseline and Week 52
Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 52
Cholesterol was measured by means of ultracentrifugation.
Time frame: Baseline and Week 52
Percent Change From Week 12 to Week 52 in LDL-C
Cholesterol was measured by means of ultracentrifugation.
Time frame: Week 12 and Week 52
Adults with fasting low-density lipoprotein cholesterol (LDL-C) ≥ 75 mg/dL and triglycerides ≤ 400 mg/dL were eligible. The first patient enrolled on 5 January 2012 and the last patient enrolled on 12 October 2012. All patients were counseled on the National Cholesterol Education Program Adult Treatment Panel III Therapeutic Lifestyle Changes diet.
| Milestone | Placebo | Evolocumab |
|---|---|---|
| Started | 303 | 602 |
| Received treatment | 302 | 599 |
| Completed | 287 | 568 |
| Not completed | 16 | 34 |
| Withdrew: Withdrawal by subject | 9 | 11 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Lost to follow-up | 2 | 11 |
| Withdrew: Other | 5 | 10 |
Cholesterol was measured by means of ultracentrifugation.
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in LDL-C at Week 52 | 6.83 ± 1.75 | -50.14 ± 1.24 |
Cholesterol was measured by means of ultracentrifugation.
| mg/dL | Placebo | Evolocumab |
|---|---|---|
| Change From Baseline in LDL-C at Week 52 | 5.1 ± 1.9 | -52.7 ± 1.4 |
An LDL-C response is defined as LDL-C level \< 70 mg/dL (1.8 mmol/L) at Week 52.
| percentage of participants | Placebo | Evolocumab |
|---|---|---|
| Percentage of Participants With an LDL-C Response at Week 52 | 6.4 (4.1 to 10.1) | 82.3 (78.8 to 85.3) |
Cholesterol was measured by means of ultracentrifugation.
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in LDL-C at Week 12 | 3.17 ± 1.31 | -54.35 ± 0.96 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol at Week 12 | 2.85 ± 0.87 | -32.30 ± 0.63 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol at Week 52 | 5.26 ± 1.16 | -28.18 ± 0.84 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 52 | 8.44 ± 1.68 | -41.82 ± 1.21 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at Week 52 | 2.94 ± 1.41 | -41.26 ± 1.02 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 52 | 6.47 ± 1.37 | -30.67 ± 0.99 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 52 | 4.46 ± 1.50 | -41.75 ± 1.09 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at Week 52 | -5.37 ± 1.62 | -27.72 ± 1.19 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Triglycerides at Week 52 | 8.99 ± 2.39 | -2.55 ± 1.72 |
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 52 | 0.35 ± 0.90 | 5.77 ± 0.65 |
Cholesterol was measured by means of ultracentrifugation.
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 52 | 31.89 ± 4.69 | 2.74 ± 3.36 |
Cholesterol was measured by means of ultracentrifugation.
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Week 12 to Week 52 in LDL-C | 2.57 ± 1.56 | 2.44 ± 1.14 |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 13/302 (4.3%) | 76/302 (25.2%) |
| Evolocumab | — | 33/599 (5.5%) | 177/599 (29.5%) |
| Event | Placebo | Evolocumab |
|---|---|---|
| Angina pectorisCardiac disorders | 2/302 | 2/599 |
| PalpitationsCardiac disorders | 0/302 | 2/599 |
| Ventricular extrasystolesCardiac disorders | 0/302 | 2/599 |
| Vertigo positionalEar and labyrinth disorders | 0/302 | 2/599 |
| Back painMusculoskeletal and connective tissue disorders | 0/302 | 2/599 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/302 | 2/599 |
| Atrial fibrillationCardiac disorders | 1/302 | 0/599 |
| Sinus bradycardiaCardiac disorders | 1/302 | 0/599 |
| Chest painGeneral disorders | 1/302 | 0/599 |
| Joint injuryInjury, poisoning and procedural complications | 1/302 | 0/599 |
| Event | Placebo | Evolocumab |
|---|---|---|
| NasopharyngitisInfections and infestations | 29/302 | 63/599 |
| Upper respiratory tract infectionInfections and infestations | 19/302 | 56/599 |
| InfluenzaInfections and infestations | 19/302 | 45/599 |
| Back painMusculoskeletal and connective tissue disorders | 17/302 | 36/599 |
| Age, Continuous(years) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Mean | 56.6 ± 10.3 | 55.9 ± 10.9 | 56.1 ± 10.7 |
| Sex: Female, Male(Participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Female | 162 | 312 | 474 |
| Male | 141 | 290 | 431 |
| Race/Ethnicity, Customized(participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 3 | 3 |
| Asian | 16 | 41 | 57 |
| Black or African American | 23 | 53 | 76 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| White | 249 | 478 | 727 |
| Other | 13 | 26 | 39 |
| Mixed Race | 2 | 0 | 2 |
| Race/Ethnicity, Customized(participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Hispanic/Latino | 17 | 33 | 50 |
| Not Hispanic/Latino | 286 | 569 | 855 |
| Background Therapy(participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Diet Only | 38 | 74 | 112 |
| Diet + Atorvastatin 10 mg | 129 | 256 | 385 |
| Diet + Atorvastatin 80 mg | 73 | 146 | 219 |
| Diet + Atorvastatin 80 mg + Ezetimibe 10 mg | 63 | 126 | 189 |
| Low-density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Mean | 104.0 ± 21.6 | 104.2 ± 22.1 | 104.1 ± 22.0 |
| Total Cholesterol(mg/dL) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Mean | 179.1 ± 27.2 | 176.8 ± 27.5 | 177.6 ± 27.4 |
| Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) Concentration(mg/dL) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Mean | 125.6 ± 26.9 | 124.2 ± 25.6 | 124.6 ± 26.1 |
7 further baseline measures are reported on the registry.
Ran from Jan 2012 to primary completion in Oct 2013, 21 months.
Results were first posted in Sep 2015, 1 year 11 months after primary completion. A results delay was requested in May 2014.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 21 months is above that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab